In addition to palbociclib, other phase III trials have evaluated the efficacy of CDK4/6 inhibitors in combination with fulvestrant in patients with HR-positive, HER 2-negative advanced breast cancer whose disease had progressed on endocrine therapy. Here, CDK4 is linked to breast cancer.